Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,064 Hematology
clinical trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Madera, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Mesa, AZ
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Omaha, NE
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Seattle, WA
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling, Phase IV
Updated: 12/31/1969
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling, Phase IV
Updated: 12/31/1969
mi
from
Aurora, CO
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling, Phase IV
Updated: 12/31/1969
mi
from
East Lansing, MI
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling, Phase IV
Updated: 12/31/1969
mi
from
Iowa City, IA
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling, Phase IV
Updated: 12/31/1969
mi
from
Washington DC,
Click here to add this to my saved trials
Bacteremia Clinical Trial
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Detroit, MI
Click here to add this to my saved trials
Bacteremia Clinical Trial
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Houston, TX
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Knoxville, TN
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Lansing, MI
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Louisville, KY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Austin, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Birmingham, AL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Des Moines, IA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Boise, ID
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Dallas, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Greenville, SC
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Kansas City, MO
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Little Rock, AR
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Madison, WI
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Morgantown, WV
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New Haven, CT
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Rochester, MN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Columbus, OH
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Duarte, CA
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Valhalla, NY
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
New Orleans, LA
Click here to add this to my saved trials
Relapsed and/or Refractory Multiple Myeloma Clinical Trial
An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Relapsed and/or Refractory Multiple Myeloma Clinical Trial
An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
mi
from
Toledo, OH
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Pensacola, FL
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Aurora, CO
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Gainesville, FL
Click here to add this to my saved trials
Anemia, Hemolytic, Autoimmune Clinical Trial
A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)
Status: Enrolling, Phase I
Updated: 3/13/2018
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Nashville, TN
Click here to add this to my saved trials
Neoplasms Clinical Trial
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Duarte, CA
Click here to add this to my saved trials
Neoplasms Clinical Trial
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Tampa, FL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Greenville, SC
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Houston, TX
Click here to add this to my saved trials
AML, Adult Clinical Trial
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Detroit, MI
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Chicago, IL
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
La Jolla, CA
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Omaha, NE
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Philadelphia, PA
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Valhalla, NY
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Orange, CA
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Washington DC,
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Status: Enrolling, Phase IV
Updated: 12/31/1969
mi
from
Detroit, MI
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Status: Enrolling, Phase IV
Updated: 12/31/1969
mi
from
Portland, OR
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Status: Enrolling, Phase IV
Updated: 12/31/1969
mi
from
Newark, NJ
Click here to add this to my saved trials
Hematology Clinical Trial
Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers
Status: Enrolling, Phase
Updated: 3/9/2018
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Buffalo, NY
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Baltimore, MD
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Cleveland, OH
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Study of AMV564 in Patients With AML
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Columbus, OH
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Study of AMV564 in Patients With AML
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Study of AMV564 in Patients With AML
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Seattle, WA
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Dallas, TX
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Westwood, KS
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Daphne, AL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Easton, PA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Gallatin, TN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Greenville, SC
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Mobile, AL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Seneca, SC
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Atlanta, GA
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Louisville, KY
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Everett, WA
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Omaha, NE
Click here to add this to my saved trials
1 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 121